{"name":"Arcutis Biotherapeutics","slug":"arcutis","ticker":"ARQT","exchange":"NASDAQ","domain":"arcutis.com","description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","hq":"Westlake Village, CA","founded":0,"employees":"354","ceo":"Frank Watanabe","sector":"Dermatology / Specialty Pharma","stockPrice":24.32,"stockChange":1.05,"stockChangePercent":4.51,"marketCap":"$3.0B","metrics":{"revenue":376072000,"revenueGrowth":81.5,"grossMargin":90.2,"rdSpend":77051000,"netIncome":-16141000,"cash":220982000,"dividendYield":0,"peRatio":19,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2011-01-01","label":"Daliresp first approved","drug":"Daliresp","drugSlug":"roflumilast","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Roflumilast Cream patent cliff ($1.2B at risk)","drug":"Roflumilast Cream","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Etrasimod patent cliff ($500M at risk)","drug":"Etrasimod","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"Daliresp","genericName":"ROFLUMILAST","slug":"roflumilast","indication":"COPD Associated with Chronic Bronchitis","status":"marketed"},{"name":"Roflumilast Cream 0.15%","genericName":"Roflumilast Cream 0.15%","slug":"roflumilast-cream-0-15","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Roflumilast Foam 0.3%","genericName":"Roflumilast Foam 0.3%","slug":"roflumilast-foam-0-3","indication":"Atopic dermatitis (topical foam formulation)","status":"phase_3"},{"name":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","genericName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","slug":"arq-151-cream-0-15-or-arq-151-cream-0-05","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-151 cream 0.15%","genericName":"ARQ-151 cream 0.15%","slug":"arq-151-cream-0-15","indication":"Plaque psoriasis","status":"phase_1"},{"name":"ARQ-151 cream 0.3%","genericName":"ARQ-151 cream 0.3%","slug":"arq-151-cream-0-3","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-151 vehicle cream","genericName":"ARQ-151 vehicle cream","slug":"arq-151-vehicle-cream","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-154","genericName":"ARQ-154","slug":"arq-154","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"Roflumilast Cream 0.05%","genericName":"Roflumilast Cream 0.05%","slug":"roflumilast-cream-0-05","indication":"Atopic dermatitis (topical)","status":"phase_3"},{"name":"Roflumilast Foam","genericName":"Roflumilast Foam","slug":"roflumilast-foam","indication":"Atopic dermatitis (topical foam formulation)","status":"phase_3"},{"name":"Topical roflumilast","genericName":"Topical roflumilast","slug":"topical-roflumilast","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ARQ-234","genericName":"ARQ-234","slug":"arq-234","indication":"Other","status":"phase_1"},{"name":"ARQ-151 cream 0.5%","genericName":"ARQ-151 cream 0.5%","slug":"arq-151-cream-0-5","indication":"Other","status":"phase_1"},{"name":"ARQ-154 Foam 0.3%","genericName":"ARQ-154 Foam 0.3%","slug":"arq-154-foam-0-3","indication":"Other","status":"phase_1"},{"name":"ARQ-252 cream 0.1%","genericName":"ARQ-252 cream 0.1%","slug":"arq-252-cream-0-1","indication":"Other","status":"phase_1"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ARQ-151 cream 0.05%","genericName":"ARQ-151 cream 0.05%","slug":"arq-151-cream-0-05","indication":"Atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"ARQ-234","genericName":"ARQ-234","slug":"arq-234","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Daliresp","genericName":"ROFLUMILAST","slug":"roflumilast","phase":"marketed","mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body.","indications":["COPD Associated with Chronic Bronchitis","Plaque psoriasis","Severe chronic obstructive pulmonary disease"],"catalyst":""},{"name":"Roflumilast Cream 0.15%","genericName":"Roflumilast Cream 0.15%","slug":"roflumilast-cream-0-15","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation by blocking the action of phosphodiesterase 4.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Roflumilast Foam 0.3%","genericName":"Roflumilast Foam 0.3%","slug":"roflumilast-foam-0-3","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","indications":["Atopic dermatitis (topical foam formulation)","Plaque psoriasis (topical foam formulation)"],"catalyst":""},{"name":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","genericName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","slug":"arq-151-cream-0-15-or-arq-151-cream-0-05","phase":"phase_3","mechanism":"ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.05%","genericName":"ARQ-151 cream 0.05%","slug":"arq-151-cream-0-05","phase":"phase_2","mechanism":"ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.","indications":["Atopic dermatitis"],"catalyst":""},{"name":"ARQ-151 cream 0.15%","genericName":"ARQ-151 cream 0.15%","slug":"arq-151-cream-0-15","phase":"phase_1","mechanism":"ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.3%","genericName":"ARQ-151 cream 0.3%","slug":"arq-151-cream-0-3","phase":"phase_3","mechanism":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.5%","genericName":"ARQ-151 cream 0.5%","slug":"arq-151-cream-0-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARQ-151 vehicle cream","genericName":"ARQ-151 vehicle cream","slug":"arq-151-vehicle-cream","phase":"phase_3","mechanism":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-154","genericName":"ARQ-154","slug":"arq-154","phase":"phase_2","mechanism":"ARQ-154 is a topical Janus kinase (JAK) inhibitor.","indications":["Moderate to severe atopic dermatitis","Moderate to severe psoriasis"],"catalyst":""},{"name":"ARQ-154 Foam 0.3%","genericName":"ARQ-154 Foam 0.3%","slug":"arq-154-foam-0-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARQ-252 cream 0.1%","genericName":"ARQ-252 cream 0.1%","slug":"arq-252-cream-0-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Roflumilast Cream 0.05%","genericName":"Roflumilast Cream 0.05%","slug":"roflumilast-cream-0-05","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","indications":["Atopic dermatitis (topical)","Plaque psoriasis (topical)"],"catalyst":""},{"name":"Roflumilast Foam","genericName":"Roflumilast Foam","slug":"roflumilast-foam","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and inflammatory cells.","indications":["Atopic dermatitis (topical foam formulation)","Plaque psoriasis (topical foam formulation)"],"catalyst":""},{"name":"Topical roflumilast","genericName":"Topical roflumilast","slug":"topical-roflumilast","phase":"phase_3","mechanism":"Topical roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation in the skin.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Arcutis Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Arcutis Biotherapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $143.1 million and a net loss of $123.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Arcutis Biotherapeutics Announces Collaboration with Pfizer to Develop and Commercialize Roflumilast Cream","summary":"Arcutis Biotherapeutics announced a collaboration with Pfizer to develop and commercialize roflumilast cream for the treatment of atopic dermatitis.","drugName":"","sentiment":"positive"},{"date":"2023-08-04","type":"regulatory","headline":"FDA Approves Roflumilast Cream for the Treatment of Atopic Dermatitis","summary":"The FDA approved roflumilast cream for the treatment of atopic dermatitis, marking a significant milestone for Arcutis Biotherapeutics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"trial","source":"simplywall.st","summary":"Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next - simplywall.st","headline":"Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"trial","source":"simplywall.st","summary":"Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results - simplywall.st","headline":"Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Arcutis Biotherapeutics (ARQT) Q4 Profitability Raises Questions For Bullish Growth Narrative - simplywall.st","headline":"Arcutis Biotherapeutics (ARQT) Q4 Profitability Raises Questions For Bullish Growth Narrative","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNRHJDUWJSQVlZeTFnNkZ2VzNONFBwMjdNbkxRUnc4UXNVbWZsRGdiUk9iRDg2OEVMYnIzbWhoYVNpb0xwZ1FKTGt0UnVucWtzU1gwT1FIckJzLXYtZWZId2d6clhmY2hSbmtmQlFTUFVuV21xMmtvX251N3FFWkpWQUZORGtyT3NHVnJWZFlNZFB3M0R5MFIyUExXa1JJeHhqLXFF?oc=5","date":"2026-01-27","type":"pipeline","source":"Yahoo Finance","summary":"Arcutis Biotherapeutics announces termination of promotion agreement with Kowa - Yahoo Finance","headline":"Arcutis Biotherapeutics announces termination of promotion agreement with Kowa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSi1obGp1bjM1ZWtjT0stdW9vNXduTkM0LUdEMVhKUF9zdHp2S09mbzFfQVZmLUhSNXNDSWpWLVlxbXVHczBkOWQySjFSOUp2M2FKekNkYzIzWTU0TnliX05hd1VUZjc3WFlVakVWSi1kZjVxQ0Z0TXZlaG1uOFl0ZURVc0ROeW1FWjVwaGZSd1V1Mkl2ZklBcjloQXR0YU1tTDMxcDg2bVRVTUVjNlRuWkthenhzMzFt?oc=5","date":"2026-01-26","type":"pipeline","source":"Stock Titan","summary":"Arcutis to sell ZORYVE to primary care docs itself after Kowa exit - Stock Titan","headline":"Arcutis to sell ZORYVE to primary care docs itself after Kowa exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNNTRLTnhFQ3gxWWU3cTFSU3E5WG5wTURQYUJXd3Ztbi1nWnU2VTNTMzNhU0VwZVNyb0NXTVdIRjl1eFNnREgwOHpPUnVoMV9uVmRmZmVUNnFrcUZMQTRLVzFiUEFuWXFHdHFHaFRCVlQtM1BqRGt6WlRKaGNZd2tVdXgyT0hpN203eHQzamZMRWdwVGxybDAzUUsybDhoZGJRbFNRY0RqY2hXZU9kXzJfX0Z6MHYzRGM?oc=5","date":"2026-01-26","type":"pipeline","source":"Investing.com","summary":"Arcutis terminates promotion agreement with Kowa for ZORYVE - Investing.com","headline":"Arcutis terminates promotion agreement with Kowa for ZORYVE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOWmNobHNYV1I3eWZxdGNQV004U2lva25VblJER3ZxYzZ2YV84LXBNaFNjelhoaGFWbkR6MVNxYTRrRDA5RURYWlJjSDJMaVF2VTRGY2Y0YWl1WmpWaHRjRW1iRFFyZDFHb1JldkxDZVVkc3hVZmppVkd5dDRCSnNXTXNncDBWT081dHk2Sk95UGxjX3c?oc=5","date":"2026-01-25","type":"pipeline","source":"Yahoo Finance","summary":"Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback - Yahoo Finance","headline":"Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQTWEzaFlmdGFIV1p5Mkhhbi0wYU1ud1Q1RnJ4NXN4WngxREIwNE9EaEZxVHdibXlNeTVZNHo0YzhVa3BvN294d2RyZmVSY1dwLURoT1Z3U01aTUk4VGJmaUYwN2k5MlRYczU2ZlR1ZlR1ZFVER3gxUTlvbk1LWmFHNENHRjRLUWtNcjdUazZPSFF1dlJac3RROENUQS1zY0pOUlE?oc=5","date":"2025-12-08","type":"earnings","source":"Seeking Alpha","summary":"Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha","headline":"Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQR1BsWTlBX0E0Y3FoZG5IODlkNWFVM3g4cy1nQmFKdXJRczlpNnNZY3lzdVF3ZEZsTkYyXzFqVDV3cm9LUWlubEJnSml6ekdpRmNGQmNwVXVSZkhUNlVWb0JETWt1YmtRbHhWdWExRW5RUGowNHE2UmV3OUlVM0xUVHpIRXAzb1d2bF9raDR1d3NaVEswQ1U3cExaT0RFUQ?oc=5","date":"2025-10-28","type":"earnings","source":"Investor's Business Daily","summary":"Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. - Investor's Business Daily","headline":"Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdFdWTXBVQm9HVlBNX3FQYnFjZFNwNUtkbFJwWllUdmpaYUlpZXBOaXlTUjJKQndqRzd2dXEySVZ3N2c2TV9saVJ2eE1UNEJkZkVUTGxfSGYwS1E0ZXdwQm9Ndk1WTjVvNExpZzlidGZyMEVxVEVUUFNJMDhtZEdtRjBCSFBUNUxZVlc1VUNYWHg0TG1ZNl83T2g4Y1VhUUlGOGp4V00zZmZVUTR5ZElNLUdOR0JWRThU?oc=5","date":"2025-10-28","type":"earnings","source":"Seeking Alpha","summary":"Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade) (ARQT) - Seeking Alpha","headline":"Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade) (ARQT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxORDU1STg1S1VuTWZtV0YxNDJlRklDcmxIMGRBRTNwcm9YMkZYQXVFRTdoY09EaTJoTVA4WHJnd1BBcmduR1VwWVJQLVBQcWF3UzFqQ0hEQnRVN29aZTVZQVpJQ3lhLWFmYWI3djVYLVh2TmhBbzhsZ3NwbzhSRWNpZlJCX2RrajJleFE?oc=5","date":"2025-09-13","type":"pipeline","source":"TIKR.com","summary":"9 of the Fastest-Growing Biotech Stocks Under $10 Billion - TIKR.com","headline":"9 of the Fastest-Growing Biotech Stocks Under $10 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOZ2o3cjFqS1RqbzNYcXBROHhYMGo4UzBBYWlxc0R2UEVteHlRcUdGaVRPc2pnZ2Fpb2g2WUhZSTVncElEYUdtakV6SXNLRW50RDd2SlVhd3JpbHFEMDFzbmo5UFdWWXAwZkV6ZkF3ODl4WEFKRE5DZnN6MlhqY2hMOXN1UW1SdVBuSFVBM2dwLXZhemgxRk94LUhUWWY?oc=5","date":"2025-03-28","type":"pipeline","source":"Investor's Business Daily","summary":"Why This IBD 50 Stock Is Outplaying The Broader Biotech Tape - Investor's Business Daily","headline":"Why This IBD 50 Stock Is Outplaying The Broader Biotech Tape - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"Roflumilast Cream","drugSlug":"roflumilast","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Etrasimod","drugSlug":"etrasimod","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":16,"phaseCounts":{"phase_1":5,"marketed":1,"phase_3":8,"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Sanofi","Novartis"],"therapeuticFocus":["Dermatology","Atopic Dermatitis","Psoriasis"],"financials":{"source":"sec_edgar","revenue":376072000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":376072000,"period":"2025-12-31"},{"value":196542000,"period":"2024-12-31"},{"value":196542000,"period":"2024-12-31"},{"value":59606000,"period":"2023-12-31"},{"value":59606000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":77051000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-16141000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":432973000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":24.32,"previousClose":23.27,"fiftyTwoWeekHigh":31.77,"fiftyTwoWeekLow":11.86,"fiftyTwoWeekRange":"11.86 - 31.77","fiftyDayAverage":24.82,"twoHundredDayAverage":21.94,"beta":1.77,"enterpriseValue":2779793920,"forwardPE":19,"priceToBook":15.83,"priceToSales":8.02,"enterpriseToRevenue":7.39,"enterpriseToEbitda":-367.7,"pegRatio":0,"ebitda":-7560000,"ebitdaMargin":-2,"freeCashflow":-15702750,"operatingCashflow":-5625000,"totalDebt":114519000,"debtToEquity":60.4,"currentRatio":3.17,"returnOnAssets":-2,"returnOnEquity":-9.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":8,"targetMeanPrice":34.75,"targetHighPrice":36,"targetLowPrice":33,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.7,"institutionHeldPercent":108.7,"sharesOutstanding":124033382,"floatShares":91900054,"sharesShort":15753892,"shortRatio":11.35,"shortPercentOfFloat":12.7,"epsTrailing":-0.13,"epsForward":1.28,"revenuePerShare":2.96,"bookValue":1.54,"officers":[{"age":57,"name":"Mr. Todd Franklin Watanabe M.A.","title":"President, CEO & Director"},{"age":70,"name":"Dr. Bhaskar  Chaudhuri Ph.D.","title":"Co-Founder & Director Emeritus"},{"age":54,"name":"Mr. Masaru  Matsuda Esq., J.D.","title":"Executive VP, Chief Legal Officer & Corporate Secretary"},{"age":53,"name":"Dr. Patrick E. Burnett M.D., Ph.D.","title":"Executive VP & Chief Medical Officer"},{"age":61,"name":"Mr. Larry Todd Edwards","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Ms. Latha  Vairavan","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Rajvir  Madan","title":"Chief Digital & Technology Officer"},{"age":null,"name":"Mr. Brian  Schoelkopf","title":"Head of Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.arcutis.com","phone":"805 418 5006"}}